EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 (the "Previous Announcement") and confirms that with effect from 22 December 2017 it will cancel 78,113 of the 205,561 Compensation Shares (as defined in the Previous Announcement (the "Cancellation"). 

As at 30 November 2017, the Company's total issued share capital consists of 457,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.

Standard form for notification of major holdings 

EKF Diagnostics Holdings plc confirms that the 6,630,032 will be cancelled.

As at 31 October 2017, the Company's total issued share capital consists of 458,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds 1,000,000 Ordinary Shares in treasury.

Standard form for notification of major holdings 

EKF Diagnostics announces an update to its prior announcement on 6 November 2015 in relation to the settlement agreement reached with the majority of the former shareholders of Selah.

Standard form for notification of major holdings 

EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2017.

EKF Diagnostics Holdings plc announces that the reduction of the Company's share capital has now been approved by the court.